Global Checkpoint Inhibitors for Treating Cancer Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

Scope of the Report:
Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.
Although YERVOY® (ipilimumab), OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab) and Tecentriq® (atezolizumab) are four indispensable medicines for cancer treatment, they also has many shortages. Firstly, they all have side effect for patient. Secondly, price of checkpoint inhibitors for treating cancer is too expensive. CTLA-4 inhibitors price is about 118.2 USD/mg in 2016. PD-1 inhibitors price is about 28.6 USD/mg in 2016. PD-L1 inhibitors price is about 30.5 USD/mg in 2016. For most patients, the price is unbearable.
The worldwide market for Checkpoint Inhibitors for Treating Cancer is expected to grow at a CAGR of roughly 28.0% over the next five years, will reach 20600 million US$ in 2024, from 4690 million US$ in 2019, according to a new study.
This report focuses on the Checkpoint Inhibitors for Treating Cancer in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Bristol-Myers Squibb(BMS)
Merck
Roche

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors

Market Segment by Applications, can be divided into
Melanoma Treatment
Bladder Cancer Treatment
Other

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Checkpoint Inhibitors for Treating Cancer product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Checkpoint Inhibitors for Treating Cancer, with price, sales, revenue and global market share of Checkpoint Inhibitors for Treating Cancer in 2017 and 2018.
Chapter 3, the Checkpoint Inhibitors for Treating Cancer competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Checkpoint Inhibitors for Treating Cancer breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Checkpoint Inhibitors for Treating Cancer market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Checkpoint Inhibitors for Treating Cancer sales channel, distributors, customers, research findings and conclusion, appendix and data source.